Market Research Logo

Respiri Ltd (RSH) - Financial and Strategic SWOT Analysis Review

Respiri Ltd (RSH) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Respiri Ltd (Respiri), formerly iSonea Ltd, is a medical technology company that develops non-invasive medical devices and mobile health applications to improve the management of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The company’s proprietary applications, software and devices will help people monitor the symptoms of their conditions and increase their awareness of risk of attack. Respiri’s proprietary technology, Acoustic Respiratory Monitoring (ARM), helps capture, store and analyze respiratory sounds objectively and without relying on patient cooperation. The company’s product portfolio includes PulmoTrack, SonoSentry, Wholter, and AirSonea. The company has operations in Australia, Israel and the US. Respiri is headquartered in Victoria, Australia.

Respiri Ltd Key Recent Developments

Jul 30,2018: Respiri: Quarterly report – appendix 4c for the period to 30 June 2018
Jun 14,2018: Respiri Announces the Appointment of New Chairman
Feb 26,2018: Respiri Reported its Half Year Ended 31 December 2017 results
Jan 29,2018: Respiri: Short CEO Update and Reaffirmation of 2018 Plans and Milestones
Dec 22,2017: Respiri Announces Appointment of Director & Board Remuneration

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Respiri Ltd - Key Facts
Respiri Ltd - Key Employees
Respiri Ltd - Key Employee Biographies
Respiri Ltd - Major Products and Services
Respiri Ltd - History
Respiri Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Respiri Ltd - Business Description
Respiri Ltd - SWOT Analysis
SWOT Analysis - Overview
Respiri Ltd - Strengths
Respiri Ltd - Weaknesses
Respiri Ltd - Opportunities
Respiri Ltd - Threats
Respiri Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Respiri Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Respiri Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Respiri Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jul 30, 2018: Respiri: Quarterly report – appendix 4c for the period to 30 June 2018
Jun 14, 2018: Respiri Announces the Appointment of New Chairman
Feb 26, 2018: Respiri Reported its Half Year Ended 31 December 2017 results
Jan 29, 2018: Respiri: Short CEO Update and Reaffirmation of 2018 Plans and Milestones
Dec 22, 2017: Respiri Announces Appointment of Director & Board Remuneration
Oct 16, 2017: Respiri Appoints Former Senior Global Pfizer Executive Mario Gattino as Chief Executive Officer
Aug 29, 2017: Respiri Announced Its Annual Financial Report for the Year Ended 30 June 2017
May 17, 2017: Respiri: Appointment of New Company Secretary
Feb 28, 2017: Respiri’s Text and App Messaging for Better Asthma Care
Feb 27, 2017: Respiri: Interim Financial Report for the Half Year Ended December 2016
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Respiri Ltd, Key Facts
Respiri Ltd, Key Employees
Respiri Ltd, Key Employee Biographies
Respiri Ltd, Major Products and Services
Respiri Ltd, History
Respiri Ltd, Subsidiaries
Respiri Ltd, Key Competitors
Respiri Ltd, Ratios based on current share price
Respiri Ltd, Annual Ratios
Respiri Ltd, Annual Ratios (Cont...1)
Respiri Ltd, Interim Ratios
Respiri Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Respiri Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Respiri Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Respiri Ltd, Performance Chart (2014 - 2018)
Respiri Ltd, Ratio Charts
Respiri Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Respiri Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report